Bone Biologics Corp (BBLG) financial statements (2022 and earlier)

Company profile

Business Address 2 BURLINGTON WOODS DRIVE,
BURLINGTON, MA 01803
State of Incorp. DE
Fiscal Year End December 31
SIC 3842 - Orthopedic, Prosthetic, and Surgical Appliances and Supplies (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7 01111
Cash and cash equivalents7 01111
Prepaid expense  00000
Deferred costs      1
Other undisclosed current assets     0 
Total current assets:7 01112
Noncurrent Assets
Property, plant and equipment   0000
Total noncurrent assets:   0000
TOTAL ASSETS:7 01112
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:0000100
Accounts payable 000000
Employee-related liabilities  00100
Interest and dividends payable     0 
Other undisclosed accounts payable and accrued liabilities0      
Debt 0   1 
Deferred compensation liability 00000 
Due to related parties 12 9   
Other undisclosed current liabilities 10  22
Total current liabilities:014110132
Noncurrent Liabilities
Long-term debt and lease obligation     66
Long-term debt, excluding current maturities     66
Liabilities, other than long-term debt  11 8  
Due to related parties  11 8  
Total noncurrent liabilities:  11 866
Total liabilities:01412109108
Stockholders' equity
Stockholders' equity attributable to parent7(14)(12)(9)(8)(9)(6)
Common stock0000000
Common stock, share subscribed but unissued, subscriptions receivable    2  
Additional paid in capital77555555493820
Accumulated deficit(70)(69)(67)(64)(59)(47)(26)
Total stockholders' equity:7(14)(12)(9)(8)(9)(6)
TOTAL LIABILITIES AND EQUITY:7 01112

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues 1,0701,070    
Gross profit: 1,0701,070    
Operating expenses(1)(1)(2)(3)(3)(18)(12)
Other undisclosed operating loss (1,070)(1,070)    
Operating loss:(1)(1)(2)(3)(3)(18)(12)
Nonoperating expense(1) (1)(2)(4)(3)(2)
Interest and debt expense(1)(1)(1)(0)(0)(0)(1)
Other undisclosed income from continuing operations before equity method investments, income taxes    001
Loss from continuing operations before equity method investments, income taxes:(2)(2)(4)(4)(7)(21)(14)
Other undisclosed income from continuing operations before income taxes1 10   
Loss from continuing operations before income taxes:(2)(2)(3)(4)(7)(21)(14)
Income tax expense(0)(0)(0)(0)(0)(0)(0)
Net loss available to common stockholders, diluted:(2)(2)(3)(4)(7)(21)(14)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(2)(2)(3)(4)(7)(21)(14)
Comprehensive loss, net of tax, attributable to parent:(2)(2)(3)(4)(7)(21)(14)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: